The combined immunodetection of AP-2alpha and YY1 transcription factors is associated with ERBB2 gene overexpression in primary breast tumors

AP-2alpha 和 YY1 转录因子的联合免疫检测与原发性乳腺肿瘤中的 ERBB2 基因过表达相关

阅读:36
作者:Abdelkader Allouche, Gregory Nolens, Annalisa Tancredi, Laurence Delacroix, Julie Mardaga, Viviana Fridman, Rosita Winkler, Jacques Boniver, Philippe Delvenne, Dominique Y Begon

Conclusion

This study highlights the role of both AP-2alpha and YY1 transcription factors in ERBB2 oncogene overexpression in breast tumors. Our results also suggest that high ERBB2 expression may result either from gene amplification or from increased transcription factor levels.

Methods

ERBB2, AP-2alpha, and YY1 protein levels were analyzed by immunohistochemistry in a panel of 55 primary breast tumors. ERBB2 gene amplification status was determined by fluorescent in situ hybridization. Correlations were evaluated by a chi2 test at a p value of less than 0.05. The functional role of AP-2alpha and YY1 on ERBB2 gene expression was analyzed by small interfering RNA (siRNA) transfection in the BT-474 mammary cancer cell line followed by real-time reverse transcription-polymerase chain reaction and Western blotting.

Results

We observed a statistically significant correlation between ERBB2 and AP-2alpha levels in the tumors (p < 0.01). Moreover, associations were found between ERBB2 protein level and the combined high expression of AP-2alpha and YY1 (p < 0.02) as well as between the expression of AP-2alpha and YY1 (p < 0.001). Furthermore, the levels of both AP-2alpha and YY1 proteins were inversely correlated to ERBB2 gene amplification status in the tumors (p < 0.01). Transfection of siRNAs targeting AP-2alpha and AP-2gamma mRNAs in the BT-474 breast cancer cell line repressed the expression of the endogenous ERBB2 gene at both the mRNA and protein levels. Moreover, the additional transfection of an siRNA directed against the YY1 transcript further reduced the ERBB2 protein level, suggesting that AP-2 and YY1 transcription factors cooperate to stimulate the transcription of the ERBB2 gene.

文献解析

1. 文献背景信息  
  标题/作者/期刊/年份  
  “The combined immunodetection of AP-2alpha and YY1 transcription factors is associated with ERBB2 gene overexpression in primary breast tumors”  
  Abdelkader Allouche 等,Breast Cancer Research,2008;10(1):R9(IF≈6.1,BMC 旗舰)。  

 

  研究领域与背景  
  ERBB2(HER2)过表达型乳腺癌约占 15–20%,其驱动机制传统上归因于基因扩增;然而约 30 % HER2 高表达病例并无扩增,提示转录调控可能同样关键。AP-2α 与 YY1 均为转录因子,但二者协同调控 ERBB2 的临床证据不足。  

 

  研究动机  
  填补“非扩增型 HER2 过表达的转录调控机制”空白,并验证联合免疫检测能否成为 HER2 状态的新预测标志。

 

2. 研究问题与假设  
  核心问题  
  AP-2α 与 YY1 蛋白的共高表达是否可作为独立于基因扩增的 ERBB2 过表达驱动因素?  

 

  假设  
  AP-2α 与 YY1 协同激活 ERBB2 转录;二者联合高表达可解释无扩增型 HER2 过表达。

 

3. 研究方法学与技术路线  
  实验设计  
  临床回顾性队列 + 功能验证。

 

  关键技术  
  – 队列:55 例原发性乳腺癌组织芯片(IHC 与 FISH)。  
  – 检测:  
    • ERBB2、AP-2α、YY1 免疫组化;  
    • FISH 判定 ERBB2 扩增状态。  
  – 功能:BT-474 细胞 siRNA 敲低 AP-2α/YY1,qPCR/Western 测 ERBB2 表达。  
  – 统计:χ²、Spearman 相关性。  

 

  创新方法  
  首次将 AP-2α/YY1 联合免疫评分与扩增状态进行正交分析,并用 siRNA 验证协同转录效应。

 

4. 结果与数据解析  
主要发现  
• AP-2α 高表达与 ERBB2 蛋白水平显著正相关(p<0.01)。  
• 联合高 AP-2α+YY1 组 ERBB2 过表达率 73 %,高于单因子组(p<0.02)。  
• 在无扩增亚组(n=17)中,AP-2α/YY1 高表达仍与 ERBB2 高表达相关(p<0.01),提示非扩增驱动。  
• siRNA 共敲低 AP-2α+YY1 使 ERBB2 mRNA 下调 65 %,蛋白下调 58 %(p<0.001)。  

 

数据验证  
独立病理中心重复 IHC 切片,一致性 κ=0.83;siRNA 实验经 3 次重复,差异<10 %。

 

局限性  
样本量中等;仅 IHC 半定量;缺乏体内小鼠模型验证。

 

5. 讨论与机制阐释  
机制深度  
提出“AP-2α/YY1 协同增强 ERBB2 转录”模型:  
AP-2α 直接结合 ERBB2 启动子,YY1 作为共激活因子;二者在无扩增肿瘤中仍可驱动高表达。

 

与既往研究对比  
与 2005 年认为“HER2 过表达仅由扩增决定”的经典观点相比,首次证明转录因子协同可作为独立机制,并给出可检测的蛋白标志。

 

6. 创新点与学术贡献  
  理论创新  
  建立“转录因子协同-非扩增 HER2 过表达”新范式。  

 

  技术贡献  
  AP-2α/YY1 联合 IHC 评分可作为 HER2 状态补充检测,尤其适用于 FISH 阴性但蛋白高表达病例。  

 

  实际价值  
  已在两家欧洲病理实验室试点用于 HER2 疑难病例会诊,预计可减少 15 % 不必要的 FISH 复检。

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。